Idioma:

A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma

Kumthekar, Priya ; Ko, Caroline H. ; Paunesku, Tatjana ; Dixit, Karan ; Sonabend, Adam M. ; Bloch, Orin ; Tate, Matthew ; Schwartz, Margaret ; Zuckerman, Laura ; Lezon, Ray ; Lukas, Rimas V. ; Jovanovic, Borko ; McCortney, Kathleen ; Colman, Howard ; Chen, Si ; Lai, Barry ; Antipova, Olga ; Deng, Junjing ; Li, Luxi ; Tommasini-Ghelfi, Serena ; Hurley, Lisa A. ; Unruh, Dusten ; Sharma, Nitya V. ; Kandpal, Manoj ; Kouri, Fotini M. ; Davuluri, Ramana V. ; Brat, Daniel J. ; Muzzio, Miguel ; Glass, Mitchell ; Vijayakumar, Vinod ; Heidel, Jeremy ; Giles, Francis J. ; Adams, Ann K. ; James, C. David ; Woloschak, Gayle E. ; Horbinski, Craig ; Stegh, Alexander H.

Science translational medicine, 2021-03, Vol.13 (584) [Periódico revisado por pares]

United States: AAAS

Texto completo disponível

Citações Citado por

Enviar para

Título:
A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma
Autor: Kumthekar, Priya ; Ko, Caroline H. ; Paunesku, Tatjana ; Dixit, Karan ; Sonabend, Adam M. ; Bloch, Orin ; Tate, Matthew ; Schwartz, Margaret ; Zuckerman, Laura ; Lezon, Ray ; Lukas, Rimas V. ; Jovanovic, Borko ; McCortney, Kathleen ; Colman, Howard ; Chen, Si ; Lai, Barry ; Antipova, Olga ; Deng, Junjing ; Li, Luxi ; Tommasini-Ghelfi, Serena ; Hurley, Lisa A. ; Unruh, Dusten ; Sharma, Nitya V. ; Kandpal, Manoj ; Kouri, Fotini M. ; Davuluri, Ramana V. ; Brat, Daniel J. ; Muzzio, Miguel ; Glass, Mitchell ; Vijayakumar, Vinod ; Heidel, Jeremy ; Giles, Francis J. ; Adams, Ann K. ; James, C. David ; Woloschak, Gayle E. ; Horbinski, Craig ; Stegh, Alexander H.
Assuntos: 60 APPLIED LIFE SCIENCES
É parte de: Science translational medicine, 2021-03, Vol.13 (584)
Notas: AC02-06CH11357; S10OD020118; SP0007167; CA151880; 199091; R01CA208783; R01NS102669; P50CA221747
USDOE Office of Science (SC)
National Institutes of Health (NIH)
Descrição: Glioblastoma (GBM) is one of the most difficult cancers to effectively treat, in part because of the lack of precision therapies and limited therapeutic access to intracranial tumor sites due to the presence of the blood-brain and blood-tumor barriers. We have developed a precision medicine approach for GBM treatment that involves the use of brain-penetrant RNA interference–based spherical nucleic acids (SNAs), which consist of gold nanoparticle cores covalently conjugated with radially oriented and densely packed small interfering RNA (siRNA) oligonucleotides. On the basis of previous preclinical evaluation, we conducted toxicology and toxicokinetic studies in nonhuman primates and a single-arm, open-label phase 0 first-in-human trial ( <ext-link ext-link-type='clintrialgov' href='NCT03020017'>NCT03020017</ext-link> ) to determine safety, pharmacokinetics, intratumoral accumulation and gene-suppressive activity of systemically administered SNAs carrying siRNA specific for the GBM oncogene Bcl2Like12 (Bcl2L12). Patients with recurrent GBM were treated with intravenous administration of siBcl2L12-SNAs (drug moniker: NU-0129), at a dose corresponding to 1/50th of the no-observed-adverse-event level, followed by tumor resection. Safety assessment revealed no grade 4 or 5 treatment–related toxicities. Inductively coupled plasma mass spectrometry, x-ray fluorescence microscopy, and silver staining of resected GBM tissue demonstrated that intravenously administered SNAs reached patient tumors, with gold enrichment observed in the tumor-associated endothelium, macrophages, and tumor cells. NU-0129 uptake into glioma cells correlated with a reduction in tumor-associated Bcl2L12 protein expression, as indicated by comparison of matched primary tumor and NU-0129–treated recurrent tumor. Our results establish SNA nanoconjugates as a potential brain-penetrant precision medicine approach for the systemic treatment of GBM.
Editor: United States: AAAS
Idioma: Inglês

Links

View this record in Osti.gov

Voltar para lista de resultados

Anterior Resultado 3 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma

United States: AAAS

Buscando em bases de dados remotas. Favor aguardar.